Wechselwirkungen · Torisel
Torisel 30 mg concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 10
HOS-208985 · Präparat HOS-154221
In an in vitro study, temsirolimus inhibited the transport of P-glycoprotein (P-gp) substrates with an IC50 value of 2 µM. In vivo, the effect of P-gp inhibition has not been investigated in a clinical drug-drug interaction study, however, recent preliminary data from a Phase 1 study of combined lenalidomide (dose of 25 mg) and temsirolimus (dose of 20 mg) seem to support the in vitro findings and suggest an increased risk of adverse events. Therefore, when temsirolimus is co-administered with medicinal products which are P-gp substrates (e.g. digoxin, vincristine, colchicine, dabigatran,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) vincristine (HOS-086219) lenalidomide (HOS-117069) dabigatran (HOS-112096) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T15:46:00Z · SHA-256 f3c5550dfcb830d2de46566ba2243d0ebed5a8365e91770a67e6d6f36e348415 · Passage 51846b71a6e4566be828cca0ba3ff7694190759e2a9b770c396a8869ffca40bc · Zeichen 4730–5325 im Abschnitt